• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to footer
BlackDoctor.org
Where Wellness & Culture Connect

Where Wellness & Culture Connect

  • Health Conditions
  • Wellness
  • Lifestyle
  • Longevity
  • Resource Centers
    • Cancer Resource Center
    • Covid Resource Center
  • Find A Doctor
  • BDO TV
Home / Health Conditions / COVID-19 / Johnson & Johnson Announces Long-Lasting Protection of Single-Shot COVID-19 Vaccine

Johnson & Johnson Announces Long-Lasting Protection of Single-Shot COVID-19 Vaccine

 
Additional data show a booster increases protection
94 percent protection in the U.S. with booster given at two months
Four-fold increase in antibodies when given at two months
12-fold increase in antibodies when booster given at six months

NEW BRUNSWICK, N.J., September 21, 2021 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced new data reinforcing the strong and long-lasting protection of its COVID-19 vaccine. New data also showed that protection against COVID-19 increases when a booster shot of the Johnson & Johnson vaccine is administered. The safety profile of the vaccine remained consistent and was generally well-tolerated when administered as a booster.

“Our large real-world evidence and Phase 3 studies confirm that the single-shot Johnson & Johnson vaccine provides strong and long-lasting protection against COVID-19-related hospitalizations. Additionally, our Phase 3 trial data further confirm protection against COVID-19-related death,” said Mathai Mammen, M.D., Ph.D., Global Head, Janssen Research & Development, Johnson & Johnson. “Our single-shot vaccine generates strong immune responses and long-lasting immune memory. And, when a booster of the Johnson & Johnson COVID-19 vaccine is given, the strength of protection against COVID-19 further increases.”

“It is critical to prioritize protecting as many people as possible against hospitalization and death given the continued spread of COVID-19. A single-shot COVID-19 vaccine that is easy to use, distribute and administer, and that provides strong and long-lasting protection is crucial to vaccinating the global population,” said Paul Stoffels, M.D., Vice Chairman of the Executive Committee and Chief Scientific Officer at Johnson & Johnson. “At the same time, we now have generated evidence that a booster shot further increases protection against COVID-19 and is expected to extend the duration of protection significantly.”

The Company has provided available data to the U.S. Food and Drug Administration (FDA) and plans to submit the data to other regulators, the World Health Organization (WHO) and National Immunization Technical Advisory Groups (NITAGs) worldwide to inform decision-making on local vaccine administration strategies, as needed.

The data are summarized below:

Johnson & Johnson single-shot vaccine showed strong and long-lasting protection in the real world
The largest real-world evidence study for a COVID-19 vaccine reported to date in the U.S. demonstrated stable vaccine effectiveness of 79 percent (CI, 77%-80%) for COVID-19-related infections and 81 percent (CI, 79%-84%) for COVID-19-related hospitalizations. There was no evidence of reduced effectiveness over the study duration, including when the Delta variant became dominant in the U.S. Sequencing data were not available for analysis. The study included 390,000 people who received the Johnson & Johnson COVID-19 vaccine versus approximately 1.52 million unvaccinated people matched on age, sex, time, three-digit zip code, and comorbidities and predictors for COVID-19 infection severity conducted from March to late July 2021.

These data were consistent with the Phase 3 ENSEMBLE trial, where strong protection against severe/critical disease and death was observed at least 28 days post-final vaccination:

  • 75 percent overall efficacy (CI, 65%-82%) against severe/critical COVID-19, across all age cohorts and all countries included in the study.
  • 74 percent efficacy in the U.S. against severe/critical COVID-19 (CI, 39%-91%); 89 percent against hospitalization (CI, 24%-100%); 83 percent against COVID-19-related death (CI, 41%-97%).

Booster shot at two months provided 94 percent protection against COVID-19 in the U.S.
The Phase 3 ENSEMBLE 2 study showed that another shot of the Johnson & Johnson COVID-19 vaccine given 56 days after the first provided:

  • 100 percent protection (CI, 33%-100%) against severe/critical COVID-19 – at least 14 days post-final vaccination.
  • 75 percent protection against symptomatic (moderate to severe/critical) COVID-19 globally (CI, 55%-87%).
  • 94 percent protection against symptomatic (moderate to severe/critical) COVID-19 in the U.S. (CI, 58%-100%).

When a booster of the Johnson & Johnson COVID-19 vaccine was given two months after the first shot, antibody levels rose to four to six times higher than observed after the single shot.

Booster shot at six months provided 12-fold increase in antibodies
When a booster of the Johnson & Johnson COVID-19 vaccine was given six months after the single shot, antibody levels increased nine-fold one week after the booster and continued to climb to 12-fold higher four weeks after the booster. All rises were irrespective of age.

The Johnson & Johnson single-shot COVID-19 vaccine, developed by its Janssen Pharmaceutical Companies of Johnson & Johnson, received an Emergency Use Authorization (EUA) in the United States on February 27, 2021 and Conditional Marketing Authorization (CMA) by the European Commission on March 11. The World Health Organization (WHO) issued Emergency Use Listing on March 12, and the Company received an interim recommendation by the Strategic Advisory Group of Experts (SAGE) on Immunization for the WHO on March 17. Many more authorizations have been granted in countries worldwide, and regulatory submissions are ongoing.

 

September 21, 2021 by Blackdoctor

Read Next Article

The Latest In COVID-19

Omicron

A Guide to Help You Keep Up With the Omicron Subvariants

Two years into the coronavirus pandemic, Americans can be forgiven if they’ve lost track of the latest variants circulating nationally and around the world. We’ve heard of the Alpha, Beta, Gamma, Delta, and Omicron variants, but a new Greek-letter variant read more about A Guide to Help You Keep Up With the Omicron Subvariants
Pfizer booster shot

FDA Authorizes Pfizer Booster Shot for Kids Ages 5 to 11

A single dose of the Pfizer booster shot can be given to 5- to 11-year-olds, the U.S. Food and Drug Administration announced today. The third shot can be given at least five months after healthy kids complete the two-dose vaccine read more about FDA Authorizes Pfizer Booster Shot for Kids Ages 5 to 11
rapid COVID tests

Biden Administration Offering 8 Additional Free COVID Tests

The White House has officially begun a third round of free rapid COVID-19 tests for Americans to order directly to their homes. This news comes as the Biden administration continues to urge Congress to pass additional pandemic funding. Each U.S. read more about Biden Administration Offering 8 Additional Free COVID Tests
traveling

Traveling Overseas? Follow This Health Checklist

As summer approaches, you may be planning a big trip for the first time since the pandemic began -- but be sure to make and follow a health checklist if you are traveling to another country, an expert advises. That read more about Traveling Overseas? Follow This Health Checklist
COVID

‘Tragic Milestone’: 1 Million American Lives Lost to COVID-19

It's a number many Americans have grimly expected but may still find hard to comprehend: Over one million of their fellow citizens killed by COVID-19. "Today, we mark a tragic milestone: one million American lives lost to COVID-19," President Joe read more about ‘Tragic Milestone’: 1 Million American Lives Lost to COVID-19
BA.2 variant

New BA.2 COVID Subvariant Taking Hold in United States

Yet another BA.2 COVID variant is spreading rapidly in the United States and is likely to become the dominant strain within weeks, according to experts. RELATED: What You Need to Know About the Omicron BA.2 Subvariant What we know about read more about New BA.2 COVID Subvariant Taking Hold in United States

Primary Sidebar

Subscribe to our newsletter

Poll

Popular Posts

  • The McGhee Sextuplets: A Family Built On LoveThe McGhee Sextuplets: A Family Built On Love
  • Top 3 Mistakes Cooking Salmon (You Should Never Make Again)Top 3 Mistakes Cooking Salmon (You Should Never Make Again)
  • Reality Star Hospitalized After Major Car Accident: “Unresponsive, But Stable”Reality Star Hospitalized After Major Car Accident: "Unresponsive, But Stable"
  • Aleisha Allen: From Actress to Speech PathologistAleisha Allen: From Actress to Speech Pathologist
  • Black Don’t Crack: Mother Of 3 Photo Goes ViralBlack Don't Crack: Mother Of 3 Photo Goes Viral

Podcast

Footer

Where Wellness & Culture Connect

BDO is the world’s largest and most comprehensive online health resource specifically targeted to African Americans. BDO understands that the uniqueness of Black culture - our heritage and our traditions - plays a role in our health. BDO gives you access to innovative new approaches to the health information you need in everyday language so you can break through the disparities, gain control and live your life to its fullest.

Connect With Us

  • Facebook
  • Instagram
  • LinkedIn
  • Twitter
  • YouTube

Learn More About

  • Hepatitis C
  • Diabetes
  • Sickle Cell
  • Mental Health
  • About Us
  • Privacy Policy
  • Advertise With Us
  • BlackDoctor.org Advertising and Sponsorship Policy
  • Daily Vitamina
  • TBH

Copyright © 2022, BlackDoctor, Inc. All rights reserved.